Target type: biologicalprocess
A G protein-coupled receptor signaling pathway initiated by cholecystokinin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:jc, PMID:11181948]
The cholecystokinin (CCK) signaling pathway is a complex and multifaceted process that plays a crucial role in regulating various physiological functions, primarily in the gastrointestinal system. It begins with the release of CCK, a peptide hormone, from endocrine cells in the small intestine in response to the presence of dietary fats and proteins. Once released, CCK binds to its specific receptor, the CCK receptor (CCKR), which is a G protein-coupled receptor (GPCR) found on the surface of various cells, including pancreatic acinar cells, gallbladder smooth muscle cells, and neurons in the brain.
The binding of CCK to CCKR triggers a cascade of intracellular signaling events:
1. **Activation of G proteins:** CCKR activation leads to the activation of heterotrimeric G proteins, specifically the Gq/11 subtype. This activation results in the dissociation of the α subunit of the G protein, which then activates phospholipase C (PLC).
2. **Production of inositol triphosphate (IP3) and diacylglycerol (DAG):** PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and DAG, which act as second messengers.
3. **Calcium signaling:** IP3 binds to IP3 receptors on the endoplasmic reticulum (ER), leading to the release of intracellular calcium (Ca2+). The increased Ca2+ concentration activates various downstream signaling pathways, including protein kinase C (PKC) activation and Ca2+-dependent exocytosis.
4. **Activation of protein kinase C (PKC):** DAG activates PKC, a serine/threonine kinase, which phosphorylates various target proteins, thereby modulating their activity and ultimately contributing to the overall cellular response.
5. **Cellular responses:** The activation of the CCK signaling pathway leads to a variety of cellular responses depending on the cell type and context:
* **Pancreatic acinar cells:** CCK signaling stimulates the release of digestive enzymes, such as amylase, lipase, and protease, from pancreatic acinar cells. This process facilitates the digestion of dietary fats and proteins.
* **Gallbladder smooth muscle cells:** CCK signaling induces the contraction of gallbladder smooth muscle cells, leading to the release of bile into the duodenum. Bile is essential for the digestion and absorption of fats.
* **Brain neurons:** CCK signaling in the brain plays a role in regulating food intake, satiety, and anxiety. It also contributes to the regulation of gastrointestinal motility and pancreatic secretion.
The CCK signaling pathway is a critical regulator of digestion, nutrient absorption, and other physiological processes. Dysregulation of this pathway can contribute to various gastrointestinal disorders, including pancreatitis, cholelithiasis, and irritable bowel syndrome. Therefore, understanding the complexities of CCK signaling is crucial for developing therapeutic strategies for these conditions.'
"
Protein | Definition | Taxonomy |
---|---|---|
Gastrin/cholecystokinin type B receptor | A cholecystokinin receptor 2 that is encoded in the genome of cow. [OMA:P79266, PRO:DNx] | Bos taurus (cattle) |
Gastrin/cholecystokinin type B receptor | A cholecystokinin receptor 2 that is encoded in the genome of dog. [OMA:P30552, PRO:DNx] | Canis lupus familiaris (dog) |
Gastrin/cholecystokinin type B receptor | A cholecystokinin receptor 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P32239] | Homo sapiens (human) |
Cholecystokinin receptor type A | A cholecystokinin receptor 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P32238] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
5-methoxytryptamine | 5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin. 5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives. | aromatic ether; primary amino compound; tryptamines | 5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist |
fluoxetine | fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder. Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group. | (trifluoromethyl)benzenes; aromatic ether; secondary amino compound | |
propranolol | propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3. Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. | naphthalenes; propanolamine; secondary amine | anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic |
indopan | alpha-methyltryptamine : A tryptamine derivative having a methyl substituent at the alpha-position. indopan: RN given refers to parent cpd without isomeric designation | tryptamines | |
paclitaxel | Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
5-methoxy-alpha-methyltryptamine | 5-methoxy-alpha-methyltryptamine: RN given refers to parent cpd without isomeric designation | tryptamines | |
loxiglumide | loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source | organic molecular entity | |
spiroglumide | spiroglumide: a CCK receptor antagonist; antigastrin; structure given in first source | ||
Pyrrolidine-1-carbonitrile | pyrrolidines | ||
enkephalin, d-penicillamine (2,5)- | DPDPE : A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond. Enkephalin, D-Penicillamine (2,5)-: A disulfide opioid pentapeptide that selectively binds to the DELTA OPIOID RECEPTOR. It possesses antinociceptive activity. | heterodetic cyclic peptide | delta-opioid receptor agonist |
ci 988 | PD 134308: selective cholecystokinin type B receptor antagonist; inhibits growth of LoVo, a human colon cancer cell line; structure given in first source | ||
a 71623 | A 71623: structure given in first source; a cholecystokinin-A receptor agonist | ||
sr 27897 | SR 27897: structure given in first source; a CCK(A) receptor antagonist | indolyl carboxylic acid | |
l 740093 | L 740093: a CCK-B receptor antagonist; structure in first source | ||
cholecystokinin 9 | cholecystokinin 9: nonapeptide | ||
devazepide | devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders. Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding. | 1,4-benzodiazepinone; indolecarboxamide | antineoplastic agent; apoptosis inducer; cholecystokinin antagonist; gastrointestinal drug |
tetragastrin | tetragastrin : A tetrapeptide composed of L-tryptophan, L-methione, L-aspartic acid and L-phenylalaninamide residues joined in sequence. Tetragastrin: L-Tryptophyl-L-methionyl-L-aspartyl-L-phenylalaninamide. The C-terminal tetrapeptide of gastrin. It is the smallest peptide fragment of gastrin which has the same physiological and pharmacological activity as gastrin. | peptidyl amide; tetrapeptide | anxiogenic; human metabolite |
asperlicin | asperlicin: cholecystokinin antagonist; isolated from Aspergillus alliaceus; structure given in first source | ||
cholecystokinin (26-33) | cholecystokinin (26-33): cholecystokinin receptor antagonists | ||
cholecystokinin (27-33), tert-butyloxycarbonyl-nle(28,31)- | cholecystokinin (27-33), tert-butyloxycarbonyl-Nle(28,31)-: cholecystokinin agonist | ||
2-(2-(5-bromo-1h-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3h)-quinazolinone | 2-(2-(5-bromo-1H-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3H)-quinazolinone: CCK2 receptor antagonist | quinazolines | |
l 365260 | L 365260: a CCK-B antagonist; structure given in first source; potent & selective CCK-B & gastrin receptor ligand; L 365260 and L 365346 are (R)- and (S)-stereoisomers, respectively | benzodiazepine | |
enkephalin, ala(2)-mephe(4)-gly(5)- | peptide | ||
sincalide | Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas. | oligopeptide | |
pentagastrin | Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. | organic molecular entity | |
yf 476 | YF 476: gastrin and CCK-B receptor antagonist; structure in first source | ||
l 365260 | |||
mart-1 antigen | MART-1 Antigen: A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells. | ||
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | |||
naluzotan | naluzotan: an antidepressant and anti-anxiety agent; structure in first source | ||
butyloxycarbonyl-tryptophyl-methionyl-aspartyl-phenylalaninamide | |||
a 803467 | A 803467: an Nav1.8 sodium channel blocker; structure in first source | ||
gastrin 17 | gastrin-17 : One of the primary forms of gastrin that is a 17-membered peptide consisting of Glp, Gly, Pro, Trp, Leu, Glu, Glu, Glu, Glu, Glu, Ala, Tyr, Gly, Trp, Met, Asp and Phe-NH2 residues joined in sequence. | gastrin | antineoplastic agent |
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source |